• Je něco špatně v tomto záznamu ?

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver

R. Indra, S. Jelínková, K. Kollárová, P. Zahumenská, J. Dvořák, Š. Dušková, H. Dračínská

. 2024 ; 74 (3) : 441-459. [pub] 20240914

Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018914

Lenvatinib is an orally effective tyrosine kinase inhibitor used to treat several types of tumors, including progressive, radioiodine-refractory differentiated thyroid cancer and advanced renal cell carcinoma. Although this drug is increasingly used in therapy, its metabolism and effects on the organism are still not described in detail. Using the rat as an experimental animal model, this study aimed to investigate the metabolism of lenvatinib by rat microsomal enzymes and cytochrome P450 (CYPs) enzymes recombinantly expressed in SupersomesTMin vitro and to assess the effect of lenvatinib on rat CYP expression in vivo. Two metabolites, O-desmethyl lenvatinib, and lenvatinib N-oxide, were produced by rat CYPs in vitro. CYP2A1 and 2C12 were found to be the most effective in forming O-desmethyl lenvatinib, while CYP3A2 was found to primarily form lenvatinib N-oxide. The administration of lenvatinib to rats caused changes in the expression of mRNA and protein, as well as the activity of various CYPs, particularly in an increase in CYP1A1. Thus, the administration of lenvatinib to rats has an impact on the level of CYPs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018914
003      
CZ-PrNML
005      
20241024111110.0
007      
ta
008      
241015s2024 pl f 000 0|eng||
009      
AR
024    7_
$a 10.2478/acph-2024-0027 $2 doi
035    __
$a (PubMed)39279523
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Indra, Radek $u Department of Biochemistry, Faculty of Science, Charles University, 128 00 Prague 2, Czech Republic $1 https://orcid.org/000000017114654X $7 uk20211108036
245    14
$a The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver / $c R. Indra, S. Jelínková, K. Kollárová, P. Zahumenská, J. Dvořák, Š. Dušková, H. Dračínská
520    9_
$a Lenvatinib is an orally effective tyrosine kinase inhibitor used to treat several types of tumors, including progressive, radioiodine-refractory differentiated thyroid cancer and advanced renal cell carcinoma. Although this drug is increasingly used in therapy, its metabolism and effects on the organism are still not described in detail. Using the rat as an experimental animal model, this study aimed to investigate the metabolism of lenvatinib by rat microsomal enzymes and cytochrome P450 (CYPs) enzymes recombinantly expressed in SupersomesTMin vitro and to assess the effect of lenvatinib on rat CYP expression in vivo. Two metabolites, O-desmethyl lenvatinib, and lenvatinib N-oxide, were produced by rat CYPs in vitro. CYP2A1 and 2C12 were found to be the most effective in forming O-desmethyl lenvatinib, while CYP3A2 was found to primarily form lenvatinib N-oxide. The administration of lenvatinib to rats caused changes in the expression of mRNA and protein, as well as the activity of various CYPs, particularly in an increase in CYP1A1. Thus, the administration of lenvatinib to rats has an impact on the level of CYPs.
650    _2
$a zvířata $7 D000818
650    12
$a chinoliny $x farmakologie $7 D011804
650    12
$a fenylmočovinové sloučeniny $x farmakologie $7 D010671
650    12
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a mužské pohlaví $7 D008297
650    12
$a játra $x účinky léků $x metabolismus $7 D008099
650    12
$a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
650    12
$a oxidace-redukce $x účinky léků $7 D010084
650    _2
$a jaterní mikrozomy $x účinky léků $7 D008862
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a messenger RNA $x metabolismus $x genetika $7 D012333
650    _2
$a inhibitory tyrosinkinasy $7 D000092004
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jelínková, Sandra $u Department of Biochemistry, Faculty of Science, Charles University, 128 00 Prague 2, Czech Republic $1 https://orcid.org/0000000339934831
700    1_
$a Kollárová, Katarína $u Department of Biochemistry, Faculty of Science, Charles University, 128 00 Prague 2, Czech Republic $1 https://orcid.org/0000000192306135
700    1_
$a Zahumenská, Petra $u Department of Biochemistry, Faculty of Science, Charles University, 128 00 Prague 2, Czech Republic $1 https://orcid.org/0009000218693864
700    1_
$a Dvořák, Josef $u Department of Biochemistry, Faculty of Science, Charles University, 128 00 Prague 2, Czech Republic $1 https://orcid.org/0009000663590257
700    1_
$a Dušková, Šárka $u Centre of Occupational Health, National Institute of Public Health, 100 42 Prague 10, Czech Republic
700    1_
$a Dračínská, Helena $u Department of Biochemistry, Faculty of Science, Charles University, 128 00 Prague 2, Czech Republic $1 https://orcid.org/0000000314771132 $7 xx0077061
773    0_
$w MED00000116 $t Acta pharmaceutica (Zagreb, Croatia) $x 1846-9558 $g Roč. 74, č. 3 (2024), s. 441-459
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39279523 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111104 $b ABA008
999    __
$a ok $b bmc $g 2201644 $s 1230887
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 74 $c 3 $d 441-459 $e 20240914 $i 1846-9558 $m Acta pharmaceutica (Zagreb, Croatia) $n Acta Pharm $x MED00000116
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace